Novavax applies to WHO for emergency listing of COVID-19 vaccine

Novavax Inc and its partner Serum Institute of India have applied to the World Health Organization for an emergency use listing of Novavax's COVID-19 vaccine, the company said on Thursday. The WHO's emergency use listing is a signal to national regulatory authorities on a product's safety and efficacy.

Novavax Inc and its partner Serum Institute of India have applied to the World Health Organization for an emergency use listing of Novavax's COVID-19 vaccine, the company said on Thursday.

The WHO's emergency use listing is a signal to national regulatory authorities on a product's safety and efficacy. It is also a prerequisite for export to several countries participating in the COVAX vaccine sharing facility.

Novavax and Serum Institute, the world's largest vaccine producer, have committed to together provide more than 1.1 billion doses to the COVAX facility, which aims to provide equitable access to COVID-19 vaccines to low- and middle-income countries. The Novavax shot is a protein-based vaccine, and has shown 90.4% efficacy overall in trials in the United States and Mexico.